Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Average Recommendation of “Reduce” by Brokerages

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has earned a consensus recommendation of “Reduce” from the six analysts that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $16.20.

Several equities analysts recently commented on the stock. Wells Fargo & Company upped their price target on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and lifted their price objective for the stock from $11.00 to $16.00 in a research note on Thursday, May 28th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Thursday, June 18th. Wall Street Zen upgraded shares of Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Finally, Truist Financial lowered their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after acquiring an additional 1,975 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Integra LifeSciences in the first quarter valued at about $277,000. Goldman Sachs Group Inc. raised its stake in Integra LifeSciences by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock valued at $36,515,000 after purchasing an additional 35,790 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Integra LifeSciences by 23.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after purchasing an additional 45,693 shares during the period. Finally, Marshall Wace LLP bought a new stake in Integra LifeSciences during the second quarter worth about $491,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Price Performance

Shares of IART stock remained flat at $18.05 on Friday. 682,936 shares of the stock were exchanged, compared to its average volume of 920,119. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $18.92. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -2.79, a price-to-earnings-growth ratio of 1.25 and a beta of 1.22. The stock’s 50 day moving average price is $15.57 and its 200-day moving average price is $12.68. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.13. The company had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The company’s revenue was up 2.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, sell-side analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.